Treatment of Patients With Metastatic Cancer Using a Major Histocompatibility Complex Class II-Restricted T-Cell Receptor Targeting the Cancer Germline Antigen MAGE-A3.

ABSTRACT: Purpose Adoptive transfer of genetically modified T cells is being explored as a treatment for patients with metastatic cancer. Most current strategies use genes that encode major histocompatibility complex (MHC) class I-restricted T-cell receptors (TCRs) or chimeric antigen receptors to genetically modify CD8⁺ T cells or bulk T cells for treatment. Here, we evaluated the safety and efficacy of an adoptive CD4⁺ T-cell therapy using an MHC class II-restricted, HLA-DPB1*0401-restricted TCR that recognized the cancer germline antigen, MAGE-A3 (melanoma-associated antigen-A3). Patients and Methods Patients received a lymphodepleting preparative regimen, followed by adoptive transfer of purified CD4⁺ T cells, retrovirally transduced with MAGE-A3 TCR plus systemi

SUBMITTER: Lu YC 

PROVIDER: S-EPMC5652397 | biostudies-literature | 2017 Oct

REPOSITORIES: biostudies-literature